← Back to Search

Other

CFI-400945 for Breast Cancer

Phase 2

Waitlist Available

Research Sponsored by Canadian Cancer Trials Group

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 24 months

Awards & highlights

Study Summary

This trial will study the effect of two drugs, CFI-400945 and durvalumab, on breast cancer.

Eligible Conditions

Breast Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 24 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~24 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Objective Response Rate of CFI-400945 given with durvalumab using RECIST 1.1

Secondary outcome measures

Disease Control Rate of CFI-400945 given with Durvalumab

Immune effects of CFI-400945 + durvalumab measured in cfDNA

Immune-Related Response Rate (iRECIST) of CFI-400945 given with durvalumab

+1 more

Side effects data

From 2022 Phase 3 trial • 867 Patients • NCT03084471

26%

Asthenia

20%

Anaemia

20%

Constipation

17%

Decreased appetite

16%

Diarrhoea

15%

Nausea

13%

Pruritus

10%

Urinary tract infection

10%

Cough

10%

Fatigue

Vomiting

Dyspnoea

Back pain

Oedema peripheral

Pyrexia

Haematuria

Abdominal pain

Arthralgia

Hypothyroidism

Blood creatinine increased

Weight decreased

Sepsis

Pneumonia

Tumour hyperprogression

General physical health deterioration

Death

Acute kidney injury

Pyelonephritis

Device related infection

Urosepsis

Pulmonary embolism

100%

80%

60%

40%

20%

Study treatment Arm

Durvalumab

Trial Design

1Treatment groups

Experimental Treatment

Group I: CFI-400945 + DurvalumabExperimental Treatment2 Interventions

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

CFI-400945

2014

Completed Phase 1

~50

Durvalumab

2017

Completed Phase 2

~3870

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

AstraZenecaIndustry Sponsor

4,265 Previous Clinical Trials

288,605,267 Total Patients Enrolled

173 Trials studying Breast Cancer

1,246,324 Patients Enrolled for Breast Cancer

University Health Network, TorontoOTHER

1,472 Previous Clinical Trials

484,989 Total Patients Enrolled

53 Trials studying Breast Cancer

29,539 Patients Enrolled for Breast Cancer

Canadian Cancer Trials GroupLead Sponsor

124 Previous Clinical Trials

67,438 Total Patients Enrolled

8 Trials studying Breast Cancer

8,709 Patients Enrolled for Breast Cancer

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the main medical conditions that CFI-400945 has been shown to help?

"CFI-400945 can be used as a treatment for unresectable stage iii non-small cell lung cancer, previously untreated metastatic ureter urothelial carcinoma."

Answered by AI

Could you please tell us how many different places are in charge of this trial?

"To make travelling as easy as possible for potential participants, the 5 enrolment sites are located in Kelowna, Toronto and Kingston. If you choose to be involved in this study, please pick the closest location to avoid any unnecessary travel."

Answered by AI

Are there any positions still available for this research project?

"Unfortunately, this trial is no longer looking for new patients. The study was originally posted on December 19th 2019 and last edited on June 29th 2022. However, there are plenty of other studies that might be a match for you. For example, right now there are 2764 trials actively recruiting breast cancer patients and 338 trials admitting patients for CFI-400945 treatment"

Answered by AI

What other research has been undertaken with CFI-400945?

"City of Hope first studied CFI-400945 in 2010. To date, there have been a total of 107 completed clinical trials and 338 live trials. Many of the open trials are located in Kelowna, British Columbia."

Answered by AI

Has CFI-400945 passed governmental approval for medicinal use?

"CFI-400945 safety was given a score of 2 by our Power team. In human trials, Phase 2 means that there is some evidence supporting safety, but not yet efficacy."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer

2019. "CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04176848.